studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 691A
Disclosures:
The following authors have nothing to disclose: Xiaoqiong Duan, Limin Chen
982
Individualized DAA treatment duration for cure in
patients with cirrhosis via modeling of early HCV kinetics
Martina Gambato 3 , Laetitia Canini 1,4 , Sabela Lens 3 , Frederik
Graw 5 , María-Carlota Londoño 3 , Susan L. Uprichard 1 , Zoe
Mariño 3 , Enric Reverter Segura 3 , Concepció Bartres 3 , Patricia
Gonzalez 3 , Scott Cotler 1 , Xavier Forns 3 , Harel Dahari 1,2 ; 1 The
Program for Experimental & Theoretical Modeling, Department
of Medicine, Division of Hepatology, Loyola University Medical
Center, Maywood, IL; 2 Theoretical Biology & Biophysics Group,
Los Alamos National Laboratory, Los Alamos, NM; 3 Liver Unit,
Hospital Clínic, IDIBAPS and CIBEREHD, Barcelona, Spain; 4 Centre
for Immunity, Infection and Evolution, University of Edinburgh,
Edinburgh, United Kingdom; 5 Center for Modeling and Simulation
in the Biosciences, BioQuant Center,, Heidelberg University, Heidelberg,
Germany
Background. While recent DAA-based regimens achieve SVR
rates of over 90%, there is still substantial interest in optimizing
length (and cost) of therapy, particularly in difficult-to-cure populations,
such as those with cirrhosis. We aimed to investigate
whether modelling of early HCV-RNA kinetics after therapy
initiation could predict the minimal treatment duration needed
to achieve SVR (cure). Methods. Fifty eight HCV patients who
received DAA-based treatment for 12, 16 or 24 weeks at a
single centre were included. HCV genotype, Child-Turcotte-
Pugh [CTP], MELD, hepatic venous pressure gradient [HVPG],
liver stiffness [LS], platelets count [PLT], albumin level [ALB]),
IL28B, and treatment regimen were recorded. Viral load was
assessed at baseline, at 4, 8 and 24 hours, at days 2, 3, 4,
7, and at weeks 2, 3 and 4 after treatment initiation (or until
target-not-detected (TND); LLOQ: HCV-RNA